See more : GEO JS Tech Group Corp. (GJST) Income Statement Analysis – Financial Results
Complete financial analysis of Apexigen, Inc. (APGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Apexigen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Devro plc (DVO.L) Income Statement Analysis – Financial Results
- InnovaQor, Inc. (VMCS) Income Statement Analysis – Financial Results
- Alior Bank S.A. (ALORY) Income Statement Analysis – Financial Results
- Spectris plc (SEPJY) Income Statement Analysis – Financial Results
- Public Power Corporation S.A. (PUPOF) Income Statement Analysis – Financial Results
Apexigen, Inc. (APGN)
About Apexigen, Inc.
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.
| Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.04M | 21.66M | 18.77M |
| General & Administrative | 9.65M | 7.29M | 5.77M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 9.65M | 7.29M | 5.77M |
| Other Expenses | 617.00K | 0.00 | 0.00 |
| Operating Expenses | 32.69M | 28.96M | 24.54M |
| Cost & Expenses | 32.69M | 28.96M | 24.54M |
| Interest Income | 0.00 | 41.00K | 421.00K |
| Interest Expense | -617.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 110.00K | 105.00K | 127.00K |
| EBITDA | -32.58M | -28.85M | -24.42M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -32.69M | -28.96M | -24.54M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 617.00K | 41.00K | 421.00K |
| Income Before Tax | -32.07M | -28.92M | -24.12M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -617.00K | -41.00K | -421.00K |
| Net Income | -31.45M | -28.88M | -23.70M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -1.59 | -0.93 | -0.76 |
| EPS Diluted | -1.59 | -0.93 | -0.76 |
| Weighted Avg Shares Out | 19.79M | 31.07M | 31.07M |
| Weighted Avg Shares Out (Dil) | 19.79M | 31.07M | 31.07M |
Is Apexigen, Inc. (APGN) Stock Outpacing Its Medical Peers This Year?
4 Penny Stocks To Buy According To Analysts & Targets Over 600%
Apexigen Announces Approximately $2.8 Million Private Placement Financing
4 Penny Stocks To Buy According To Insiders & Targets Up To 347%
Apexigen Announces New Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, at ASCO Gastrointestinal Cancers Symposium 2023
Apexigen Stock Soars After Analyst Rating, Is It Time to Buy?
Form 8.3 - Applegreen plc
Form 8.3 - Applegreen plc
Form 8.3 - APPLEGREEN PLC
Form 8.3 - Applegreen plc
Source: https://incomestatements.info
Category: Stock Reports